Monitor for further dilutive transactions given the company's reliance on convertible debt. The extreme share increase suggests financial distress or aggressive capital structure management. Short-term bearish due to dilution; long-term impact depends on use of proceeds and future financing needs.
Price Chart
Executive Summary
Regen BioPharma issued 77,849,847 common shares to satisfy $68,723 in convertible debt, accrued interest, and fees. The issuance was conducted unregistered under Section 4(a)(2) of the Securities Act and increases outstanding shares by approximately 56%, indicating significant dilution for existing shareholders.
Key Financial Metrics
Key Facts
- Issued 77,849,847 common shares between Feb 4 and Feb 27, 2026
- Shares issued to satisfy $53,474 principal, $4,249 interest, and $11,000 fees on convertible debt
- No cash raised — transaction was debt conversion
- Shares issued under Section 4(a)(2), unregistered
- Post-issuance shares outstanding: 212,318,424
- Dilution: new shares represent 56.3% of pre-issuance outstanding shares
Financial Impact
Approximately 56.3% increase in shares outstanding, diluting existing shareholders. Debt reduction of $68,723 improves balance sheet but at substantial equity cost.
Risk Factors
- Significant shareholder dilution reduces per-share value and future earnings power
- Potential for continued dilution if company relies on convertible debt financing
- Low-priced share issuance could signal financial distress
- OTC listing increases susceptibility to dilutive capital raises
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-008837 |
| Document: 0001493152-26-008837-index-headers.html | 0001493152-26-008837 |
| Document: 0001493152-26-008837-index.html | 0001493152-26-008837 |
| Document: 0001493152-26-008837.txt | 0001493152-26-008837 |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers